Toxicity is Primary Concern in Early-Phase CAR T-Cell Trials, Guidance Says
April 1, 2022
The FDA expects early-phase CAR T-cell therapy trials to focus primarily on the risks of toxicity, according to a new draft guidance that also addresses manufacturing and preclinical considerations in developing CAR T-cell therapies.